Home Blog Page 14

Torrent Pharma Q2 FY26 Net Profit Up 30% to ₹591 Crore

0

Torrent Pharmaceuticals reported a 30% increase in net profit, reaching ₹591 crore for Q2 FY26. Revenue increased by 14% year-over-year to ₹3,302 crores. The company’s operating EBITDA stood at ₹1,083 crores with a margin of 32.8%. Strong performance in key markets like India and the US drove the results. A recent acquisition is expected to further boost growth.

Strong Q2 FY26 Performance

Torrent Pharmaceuticals announced a strong financial performance for Q2 FY26, with net profit increasing by 30% to ₹591 crore. Revenue for the quarter reached ₹3,302 crores, a 14% increase compared to the same period last year. Operating EBITDA stood at ₹1,083 crores, representing a margin of 32.8%.

Key Financial Highlights

  • Revenue: ₹3,302 crores (up 14% YoY)
  • Operating EBITDA: ₹1,083 crores (up 15% YoY)
  • Operating EBITDA Margin: 32.8%
  • Net Profit: ₹591 crores (up 30% YoY)

Segmental Performance

The company experienced growth in key markets:

  • India: Revenues increased by 12% to ₹1,820 crores, driven by strong performance in focus therapies.
  • Brazil: Revenues increased by 21% to ₹318 crores (13% in constant currency).
  • United States: Revenues increased by 26% to ₹337 crores (21% in constant currency).
  • Germany: Revenues increased by 5% to ₹303 crores (-5% in constant currency due to supply chain issues).

Recent Developments

Torrent Pharma received approvals from the Competition Commission of South Africa and the Competition Commission of India for its acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited. This acquisition is anticipated to contribute significantly to future growth. The transaction involves acquiring 46.39% equity stake and merging JB Pharma with Torrent. Exceptional items for the quarter pertain to regulatory and statutory filing fees related to this transaction.

Full Year Outlook

The company is expected to continue its growth trajectory, driven by strong performance in key markets, new product launches, and the integration of JB Pharma. R&D expenditure for the quarter was ₹156 crores, representing 5% of revenue. The company remains focused on investing in R&D to drive future growth.

Source: BSE

Global Health Q2 FY26 Revenue Up 14.9%, Noida Hospital Operational

0

Global Health (Medanta) announced a 14.9% increase in revenue to INR 10,992 million for Q2 FY26. The newly opened Medanta Noida contributed INR 39 million in revenue. EBITDA ex Noida grew by 13.7% year-over-year. The hospital group is expanding with new facilities and increased bed capacity, particularly in Patna, and saw strong growth in international patient revenue.

Financial Performance

Global Health Limited reported strong financial results for Q2 FY26:

  • Total Income: Increased by 14.8% year-over-year to INR 11,189 million.
  • Revenue from Operations: Up 14.9% to INR 10,992 million.
  • EBITDA (ex Noida): Grew by 13.7% year-over-year to INR 2,804 million.
  • Net Profit: Increased by 21.1% year-over-year to INR 1,584 million.

Noida Hospital Commences Operations

Medanta Noida began operations in September 2025, contributing INR 39 million in revenue during the quarter. However, it also incurred an EBITDA loss of INR 197 million due to initial ramp-up costs. The facility currently operates with 226 beds, 81 ICU beds, and 5 operating theatres.

Expansion and Bed Capacity

Medanta is expanding its facilities:

  • Patna: Added 37 new beds during the quarter.
  • Mumbai: Plans to build a 500+ bed super-specialty hospital in Oshiwara.
  • Guwahati: Acquired a 3.5-acre land parcel for a new hospital.

Operational Highlights

  • Occupied bed days increased by 7.7% year-over-year.
  • ARPOB grew by 5.5% year-over-year to INR 65,570.
  • International Patients Revenue increased by 48.5% year-over-year to INR 762 million.

Comments from Leadership

Mr. Pankaj Sahni, Group CEO and Director, stated the company launched its sixth hospital in Noida in September 2025. Over 150 doctors have joined the hospital, supported by advanced medical technologies. He also highlighted the company delivered a strong performance, with Revenue Growth of 15% year-on-year.

Source: BSE

Bayer CropScience Q2 Revenue at ₹15,534 Million, Interim Dividend Declared

0

Bayer CropScience Limited announced its unaudited results for Q2 (Jul-Sep) and H1 ended September 30, 2025. Q2 revenue from operations reached ₹15,534 million. The Board declared an interim dividend of ₹90 per equity share. The company noted that unusually prolonged rainfall impacted field activities, while the corn seed business maintained growth.

Financial Performance

Bayer CropScience Limited (BCSL) announced its unaudited financial results for the quarter and half-year ended September 30, 2025. Key highlights from the announcement include:

Q2 (Jul-Sep) 2025:

  • Revenue from Operations: ₹15,534 million compared to ₹17,382 million in the corresponding period of FY 2024-25.
  • Profit Before Tax: ₹2,003 million, compared to ₹1,901 million in the previous year.

H1 (Apr-Sep) 2025:

  • Revenue from Operations: ₹34,680 million compared to ₹33,696 million for the corresponding period in FY 2024-25.
  • Profit Before Tax: ₹5,355 million, compared to ₹5,059 million in the corresponding period in FY 2024-25.

Dividend Announcement

The Board of Directors declared an interim dividend of ₹90/- per equity share for the financial year ending March 31, 2026, amounting to ₹4045 million.

Management Commentary

Simon Wiebusch, Vice Chairman & Managing Director and CEO, BCSL, commented that unusually prolonged rainfall impacted product placement, resulting in lower revenue from the Crop Protection portfolio. However, the corn seed business continued its growth. He emphasized the company’s resilience and focus on preparedness.

Vinit Jindal, Executive Director and Chief Financial Officer, noted a solid performance with Profit After Tax up 12% in Q2 and 10% in H1 year-over-year. This was attributed to a favorable sales mix, stabilized input costs, lower provisioning for doubtful receivables, and disciplined cost management.

Source: BSE

Avenue Supermarts Opens New Store in Greamspet, Chittoor

0

Avenue Supermarts has announced the opening of a new store in Greamspet, Chittoor (Andhra Pradesh). With this addition, the total number of stores as of November 7, 2025, stands at 437. This expansion reflects the company’s ongoing growth strategy and commitment to increasing its retail presence.

New Store Launch

Avenue Supermarts has announced the opening of a new retail location. The latest store is located in Greamspet, Chittoor, situated in the state of Andhra Pradesh.

Total Store Count

As of November 7, 2025, with the opening of the new store, the total number of Avenue Supermarts stores now stands at 437 locations across India. This reflects the company’s continued expansion efforts.

Source: BSE

Torrent Pharma Reports Strong Q2 FY26 Results, PAT Up 30%

0

Torrent Pharmaceuticals announced strong Q2 FY26 results, with revenue up 14% YoY to ₹3,302 crores. Operating EBITDA increased by 15% YoY to ₹1,083 crores, and net profit after tax rose by 30% YoY to ₹591 crores. The company’s performance was driven by strong branded business results. India revenues increased by 12%. The company’s operating EBITDA margin was 32.8%.

Financial Highlights

Torrent Pharmaceuticals announced its financial results for Q2 FY26, showcasing significant growth in revenue and profitability:

  • Revenue: Increased by 14% year-over-year to ₹3,302 crores.
  • Operating EBITDA: Grew by 15% year-over-year to ₹1,083 crores.
  • Operating EBITDA Margin: Reached 32.8%.
  • Net Profit After Tax: Surged by 30% year-over-year to ₹591 crores.

Segment Performance

The company experienced notable performance across key geographic segments:

  • India: Revenues increased by 12% to ₹1,820 crores.
  • Brazil: Revenues increased by 21% to ₹318 crores.
  • United States: Revenues increased by 26% to ₹337 crores.
  • Germany: Revenues increased by 5% to ₹303 crores.

Strategic Developments

Torrent Pharma’s strong performance is underscored by strategic moves aimed at expanding its market presence. They have entered into a definitive agreement to acquire a controlling stake in JB Chemicals & Pharmaceuticals Ltd, which is still subject to statutory approvals. The exceptional items for this quarter pertain to regulatory and statutory fees related to this proposed transaction.

Key Ratios & Metrics

Several key financial ratios reflect a positive outlook:

  • Debt-Equity Ratio: 0.31 times.
  • Debt Service Coverage Ratio: 2.98 times.
  • Interest Service Coverage Ratio: 17.15 times.
  • Net Profit Margin: 17.9%.

Source: BSE

AstraZeneca India Revenue Up 37%, Seven Approvals in H1

0

AstraZeneca Pharma India reported a 37% revenue increase for Q2 2025-26. The company also highlighted seven new drug approvals in the first half of the fiscal year. Growth momentum occurred across Oncology, Biopharmaceuticals, and Rare Diseases, strengthening AstraZeneca’s market position. This performance reflects the company’s commitment to scientific innovation and patient access.

Strong Financial Performance

AstraZeneca Pharma India Limited announced a revenue growth of 37% for the quarter ended September 30, 2025 (Q2 2025-26). This substantial growth reflects strong execution and positive momentum across key therapeutic areas.

Key Financial Highlights (INR Mn)

  • Total Revenue (Q2 2025): 5,590.9
  • Total Revenue (H1 2025): 10,854.0
  • Profit Before Exceptional Items and Tax (Q2 2025): 781.1
  • Profit After Exceptional Item and Tax (Q2 2025): 542.2

New Drug Approvals

The company achieved seven new regulatory approvals in the first half of the fiscal year, strengthening its leadership across various therapeutic areas. Key approvals include:

  • Durvalumab: Approved for endometrial cancer and muscle-invasive bladder cancer (MIBC).
  • Eculizumab: Launched for atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
  • Osimertinib: Approved for NSCLC in combination with chemotherapy and as a monotherapy.
  • Trastuzumab deruxtecan: Approved for HER2-low and HER2-ultralow metastatic breast cancer.
  • Benralizumab: Approved for eosinophilic granulomatosis with polyangiitis (EGPA).

Growth Across Key Therapeutic Areas

AstraZeneca experienced growth across its core therapeutic areas:

  • Oncology: Driving significant revenue.
  • Biopharmaceuticals (CVRM, R&I, V&I): Contributing strongly to overall growth.
  • Rare Disease: Showing promising expansion.

Commitment to Innovation and Patient Access

AstraZeneca remains focused on translating cutting-edge science into life-changing medicines for patients in India, shaping a more accessible and outcomes-driven healthcare ecosystem.

Source: BSE

Signature Global Achieves INR 12.0 Billion Revenue in H1FY26

0

Signature Global announced revenue of INR 12.0 bn for H1FY26 and INR 3.3 bn for Q2FY26. Adjusted gross profit margin improved to 29% in H1FY26 and 35% in Q2FY26. Pre-sales reached INR 46.6 bn in H1FY26. The company acquired approximately 2.3 mn sqft of land during H1FY26. Net debt stood at INR 9.7 bn.

Financial Highlights for H1FY26 and Q2FY26

Signature Global reported its key financial updates, showcasing growth and strategic developments.

Revenue

The company achieved a revenue from operations of INR 12.0 bn in H1FY26 and INR 3.3 bn in Q2FY26, compared to INR 11.5 bn and INR 7.5 bn in the corresponding periods of the previous year, respectively.

Profitability

Adjusted gross profit margin stood at 29% for H1FY26 and 35% for Q2FY26. This represents a notable increase from 23% and 20% in H1FY25 and Q2FY25, respectively. The company reported a loss after tax of INR 0.12 bn in H1FY26 and INR 0.46 bn in Q2FY26.

Key Operational Updates

The company also provided updates on its operational performance.

Pre-Sales and Realization

Pre-sales reached INR 46.6 bn in H1FY26 and INR 20.2 bn for Q2FY26. Average sales realization increased to INR 15,731 per sq. ft. in H1FY26.

Collections and Business Development

Collections amounted to INR 18.6 bn in H1FY26 and INR 9.3 bn in Q2FY26. The company expanded its land holdings, acquiring approximately 2.3 mn sqft of development potential during H1FY26, including 33.47 acres in Q2FY26.

Debt

Net debt was reported at INR 9.7 bn at the end of H1FY26.

Operational & Financial Data

Particulars Q2FY26 Q2FY25 Q1FY26 YOY (%) QoQ (%) H1FY26 H1FY25 YOY (%) FY25
Pre-sales 20.2 27.8 26.4 (27%) (23%) 46.6 59.0 (21%) 102.9
No. of units 560 1,053 778 (47%) (28%) 1,338 2,021 (34%) 4,130
Area (mn.Sq.ft.) 1.34 2.38 1.62 (44%) (17%) 2.96 4.41 (33%) 8.26
Collections 9.3 9.2 9.3 1% 18.6 21.3 (13%) 43.8
Net Debt 9.7 9.7 8.8
Revenue from operation 3.3 7.5 8.7 (56%) (62%) 12.0 11.5 4% 25.0
Profit /(loss) after tax (0.46) 0.04 0.34 (0.12) 0.11 1.01
Adjusted gross profit margin 35% 20% 27% 29% 23% 31%
Adjusted EBITDA margin (7%) 10% 12% 6% 11% 14%

Source: BSE

Hindustan Aeronautics Enters Agreement with General Electric for LCA Mk1A Engines

0

Hindustan Aeronautics Limited (HAL) has entered into an agreement with General Electric Company, USA, on November 7, 2025. The agreement covers the supply of 113 units of F404-GE-IN20 engines and a support package for the execution of the 97 LCA Mk1A programme. Engine deliveries are scheduled to commence from 2027 and continue until 2032. The contract for 97 LCA Mk 1A was originally signed in September 2025.

HAL Secures Engine Supply Agreement

Hindustan Aeronautics Limited (HAL) has formalized an agreement with General Electric Company (GE) to procure engines for its Light Combat Aircraft (LCA) Mk1A program. The agreement was executed on November 7, 2025.

Engine Details and Delivery Timeline

The agreement with General Electric encompasses the procurement of 113 units of F404-GE-IN20 engines. These engines, along with a comprehensive support package, are designated for the execution of 97 LCA Mk1A aircraft programme. Deliveries of the engines are scheduled to span from 2027 to 2032, ensuring a steady supply to meet production targets.

Background of LCA Mk1A Programme

The initial contract for the 97 LCA Mk 1A aircraft had previously been signed in September 2025, marking a key milestone in the indigenous defence production initiative. This new engine agreement further solidifies the programme’s progress by securing the necessary engine supply for the manufacturing phase.

Source: BSE

Bayer CropScience Interim Dividend Declared at ₹90 per Share

0

Bayer CropScience has announced an interim dividend of ₹90 per equity share, with a face value of ₹10 each, for the financial year 2025-26. The record date for determining shareholders eligible for the dividend is November 14, 2025, and the payment date is set for December 03, 2025. This decision was made at a Board of Directors meeting held on November 07, 2025.

Interim Dividend Details

The Board of Directors of Bayer CropScience declared an interim dividend during their meeting held on November 07, 2025. The declared dividend is ₹90 per equity share.

Dividend Amount and Financial Year

The interim dividend of ₹90 is applicable for each equity share with a face value of ₹10. This dividend is intended for the financial year 2025-26.

Important Dates

Key dates associated with this dividend announcement include:

  • Record Date: Friday, November 14, 2025
  • Payment Date: Wednesday, December 03, 2025

Purpose of the Dividend

The purpose of this announcement is to inform stakeholders about the interim dividend declared by Bayer CropScience.

Source: BSE

Patanjali Foods Q2 FY26 Earnings Call Transcript Highlights FMCG Growth Strategy

0

Patanjali Foods reported a 20.95% increase in revenue to ₹9,798.84 crores for Q2 FY26, with EBITDA at ₹603.32 crores. The company is strategically shifting towards a focused FMCG enterprise, aiming for 50% of revenue from the FMCG segment in the next few years. The FMCG segment contributed 29.44% to revenue in Q2 FY26, and the company is working on improving margins. The company crossed 1 lakh hectares (1,00,997) of land under palm oil cultivation.

Financial Performance

In Q2 FY26, Patanjali Foods’ revenue stood at approximately ₹9,798.84 crores, reflecting a year-on-year growth of 20.95%. Total EBITDA reached ₹603.32 crores, marking a year-on-year increase of 22.17% with an EBITDA margin of 6.13%. The Profit After Tax (PAT) also saw a partial increase, boosted by a tax refund from previous years.

Segment Performance

The Edible Oils segment recorded revenue of ₹6,971 crores, with a year-on-year growth of 17.17%, and branded edible oils accounted for 76% of total sales. The Oil Palm Plantation business reported quarterly revenue of ₹599.43 crores, with a margin of 24.16%. The company has expanded its area under palm oil cultivation, surpassing 1 lakh hectares. Following GST changes, nearly 85% of Patanjali’s portfolio is now in the 5% bracket. The reclassified FMCG segment contributed 29.44% of the revenue in Q2 FY26 and revenue stood at ₹2,914 crores, marking a 34.3% Q-on-Q growth. The segmental EBITDA margin stood at 12.28%.

Growth & Outlook

Patanjali Foods is strategically focused on deepening market presence, promptly addressing consumer behavior, and strengthening brand building. The company anticipates a 300 to 400 basis points increase in volumes due to GST developments, enhancing market penetration and expanding distribution reach. Over the next four years, Patanjali Foods aims to achieve a 50:50 share between edible oils and FMCG businesses, with the FMCG segment expected to drive approximately 75% of profits.

Q&A Highlights

The company aims for 8-10% growth in the food business and about 15% in the HPC (Home and Personal Care) segment. Management mentioned a commitment to natural, healthy, organic, wellness, and Ayurvedic products to gain a competitive edge. They highlighted that Q3 and Q4 typically contribute more than 60-65% of the edible oils business.

The company also disclosed that revenues in the HPC (Home and Personal Care) business reached ₹659 crores in the second quarter.

Source: BSE